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Abstract 
Aims Telemonitoring (TM) and structured telephone support (STS) have the potential to deliver specialized 
management to more patients with chronic heart failure (CHF), but their efficacy is still to be proven. The 
aim of this meta-analysis was to review randomized controlled trials (RCTs) of TM or STS for all-cause 
mortality and all-cause and CHF-related hospitalizations in patients with CHF, as a non-invasive remote 
model of a specialized disease-management intervention. 
Methods and results We searched all relevant electronic databases and search engines, hand-searched 
bibliographies of relevant studies, systematic reviews, and meeting abstracts. Two reviewers independently 
extracted all data. Randomized controlled trials comparing TM or STS to usual care in patients with CHF were 
included. Studies that included intensified management with additional home or clinic-visits were excluded. 
Primary outcomes (mortality and hospitalizations) were analysed; secondary outcomes (cost, length of stay, 
and quality of life) were tabulated. Thirty RCTs of STS and TM were identified (25 peer-reviewed publications 
(n= 8323) and five abstracts (n= 1482)). Of the 25 peer-reviewed studies, 11 evaluated TM (2710 
participants), 16 evaluated STS (5613 participants) with two testing both STS and TM in separate 
intervention arms compared with usual care. Telemonitoring reduced all-cause mortality {risk ratio (RR) 0.66 
[95% confidence interval (CI) 0.54–0.81], P< 0.0001 }and STS showed a similar, but non-significant trend [RR 
0.88 (95% CI 0.76–1.01), P= 0.08]. Both TM [RR 0.79 (95% CI 0.67–0.94), P= 0.008], and STS [RR 0.77 (95% CI 
0.68–0.87), P< 0.0001] reduced CHF-related hospitalizations. Both interventions improved quality of life, 
reduced costs, and were acceptable to patients. Improvements in prescribing, patient-knowledge and self-
care, and functional class were observed. 
Conclusion Telemonitoring and STS both appear effective interventions to improve outcomes in patients 
with CHF. Systematic Review Number: Cochrane Database of Systematic Reviews. 2008:Issue 3. Art. No.: 
CD007228. DOI: 10.1002/14651858.CD007228. 
 
 
 
Introduction 
Chronic heart failure (CHF) specialized disease management programmes improve survival and quality of life, 
reduce rehospitalization, and increase the implementation of evidence-based practice.1,2 However, most of 
the successful CHF disease management programmes have been built around close clinical follow-up. The 
need for intense face-to-face follow-up strategies limits the number of patients who can participate in these 
programmes. 
Structured telephone support (STS) is monitoring and/or self-care management delivered using simple 
telephone technology (data may have been collected and stored by a computer). Telemonitoring (TM) is 
digital/broadband/satellite/wireless, or blue-tooth transmission of physiological data e.g. electrocardiogram, 
blood pressure, weight, pulse oximetry, respiratory rate, and other data (self-care, education, lifestyle 
modification, and medicine administration). Both models of care have the potential to provide access to 
specialist care for a much larger number of patients across a much greater geography and might reduce the 
costs of care. These systems can assist directly in patient management, transferring the burden of care from 
health professionals and involve the patient in supported self-care.3,4 However, it is still not clear as to 
whether or not these interventions when delivered as the sole disease management intervention improve 
patient outcomes.5,6 
This review, published in the Cochrane Database of Systematic Reviews 20107 updates a previously 
published review of remote monitoring strategies for CHF that included 10 trials of STS and five of TM.5 
Since the first review, a number of large trials have been published reporting outcomes on both STS and TM. 
We have focused on the same primary outcomes (all-cause mortality, CHF-related hospitalization, and all-
cause hospitalization) and secondary outcomes: length of stay, health-related quality of life, healthcare 
costs, and acceptability of the intervention to patients with CHF. Specifically, we have examined the benefits 
of STS or TM on a number of important outcomes in patients with CHF when compared with standard care, 
where STS or TM is the primary model of specialized disease-management intervention. 
Methods    As per our protocol8 we applied the Cochrane methodology9 for this review.7 The specific 
eligibility criteria of included studies are presented in Table 1. 
  
Inclusion and exclusion criteria. 
Information sources and search strategies 
As per the Cochrane Heart Group protocol,9 all known relevant search engines and electronic databases 
were utilized for the review update period from January 2006 to November 2008. These included CENTRAL; 
MEDLINE; EMBASE; CINAHL; AMED; Science Citation Index Expanded; DARE; no date limit: National Research 
Register; IEEE Xplore; OAIster; Google Scholar; Informit; Vivisimo; Australian Digital Theses Programme, and 
Proquest Digital Dissertations. Bibliographies of relevant studies and systematic reviews were hand-
searched. Abstracts from the following conferences were also hand-searched for the years 2006, 2007, and 
2008: European Society of Cardiology (ESC) Congress; American College of Cardiology Annual Scientific 
Sessions; American Heart Association Scientific Sessions; Heart Failure Society of America Annual Scientific 
Meeting; ESC Heart Failure Congress; ESC Spring Meeting of Cardiovascular Nursing; World Congress of Cardiology 
(2006, 2008); and the Asia-Pacific Heart Failure Congress (2008). Keywords included: heart failure, cardiac failure, 
telehealth, telephone, telemonitoring and disease-management. Language restrictions were not applied. Full details of 
search strategies are available.7 
Study selection 
Randomized controlled trials (RCT) of STS or TM compared with usual care were eligible to be included in the 
meta-analysis if they were published in full in a peer-reviewed journal.9 Studies that were published as 
abstracts only were included in sensitivity meta-analyses.9 This decision was supported by a publication, co-
authored by a member of this review team, which demonstrated that substantial potential discrepancies 
between results presented in meeting abstracts compared with final peer-reviewed publications.10 
Data collection process 
Two expert reviewers (S.C.I. and R.A.C.) independently reviewed the results of each search according to the 
inclusion and exclusion criteria with a standardized data extraction tool and also applied standard scales to 
judge study quality and risk of bias.9 A third reviewer (J.G.F.C.) adjudicated.9 
Data and analysis 
Meta-analyses of the primary outcomes (all-cause mortality, CHF-related, and all-cause hospitalizations) 
were performed according to Mantel–Haenzel methods, using a fixed effects model, risk ratios (RR), 
intention-to-treat, and assessment of statistical heterogeneity using the I2 statistic.9 All analyses were 
performed using Review Manager (RevMan) Version 5.0 (Copenhagen: The Nordic Cochrane Centre, 
Cochrane Collaboration, 2008).9 Secondary outcomes such as quality of life, cost effectiveness and 
adherence and acceptance were measured using multiple tools across the studies. To summarize these 
outcomes results have been tabulated and described. Due to variances in the way length of stay was 
calculated and reported in the included studies, this outcome was tabulated as opposed to pooled into a 
meta-analysis. 
Sensitivity analysis 
Data from included studies published only as abstracts were added to the meta-analyses of the primary 
outcomes to assess whether publication status made any difference to the result, including the level of 
heterogeneity. A second sensitivity analysis was performed to assess the impact of length of follow-up on 
the primary outcomes for full peer-reviewed publications only, excluding studies with a follow-up period of 6 
months or less. 
Results 
Study selection 
Overall, 322 publications from 7952 citations were identified as potentially relevant studies and full copies 
were retrieved and assessed. Exclusions are detailed in Figure 1. 
 
Study characteristics                                                                                                                                                                     
Thirty RCTs of STS and TM were identified, which included 9560 participants (Table 2). These include 16 
studies of STS14–18,21–23,25–30,32,33 (two of which were published abstracts14,23) 12 studies of TM34–36,38–45,47 (three 
of which were published abstracts36,43,47), and two studies with both STS and TM intervention arms 
compared with usual care.11,13 The included populations were from seven countries (Table 2). 
 
 
 Description of included studies. 
Twenty-five studies were published as full peer-reviewed publications (16 STS, n = 5613 and 11 TM, n = 
2710). Two studies11,13 had two separate intervention arms (STS vs. TM vs. usual care) and each was 
considered as a separate comparison with usual care (and are included in the aforementioned counts). One 
study included two STS arms, one of which used standard telephone equipment and the other a videophone; 
for our analyses these two intervention arms were combined as STS.33 
Risk of bias 
Analysis of the distribution in the funnel plots (not shown) demonstrated a strong publication bias towards 
positive outcomes in the included studies.7,9 A summary of the risk of bias analysis is presented in Table 3. 
The heterogeneity within the studies ranged from low (for all-cause mortality, I2 = 0%) to substantial (for all-
cause hospitalizations, STS I2 = 24%; TM I2 = 78%) (Figures 2–4) (I2 statistic low = 0–40%; moderate = 30–
60%; substantial = 50–90%, considerable = 75–100%).9 
Assessment of bias of included studies. 
 All-cause mortality 
Fifteen studies of STS11,13,15–18,21,22,25,26,28–30,32,33 and 11 studies of TM11,13,34,35,38–42,44,45 measured the effect on 
the risk of all-cause mortality (Figure 2). Telemonitoring was effective in reducing the risk of all-cause 
mortality in patients with CHF, with a 34% reduction in the risk of mortality observed [RR 0.66 95% 
confidence interval (CI) 0.54–0.81, P < 0.0001, I2 = 0%]. A similar non-significant trend was noted for STS [RR 
0.88 (95% CI 0.76–1.01), P = 0.08, I2 = 0%]. 
 Addition of studies published as abstracts14,23,36,43,47 had no substantial impact on the results [STS: RR 0.85, 
(95% CI 0.75–0.97), I2 = 0%, P = 0.02; TM: RR 0.68, (95% CI 0.57–0.82), I2 = 0%, P < 0.0001] nor did exclusion 
of studies lasting 6 months or less15,21,25,28,29,32,41,44,45 [STS: RR 0.87, (95% CI 0.74–1.02), I2 = 0%, P = 0.08; TM: 
RR 0.69, (95% CI 0.55–0.86), P = 0.0009, I2 = 0%]. 
Chronic heart failure-related hospitalization 
Thirteen studies of STS11,13,15,16,21,22,25–30,32 and four studies of TM11,13,40,42 examined the effect of these 
interventions on the risk of CHF-related hospitalization (Figure 3). Structured telephone support reduced the 
proportion of patients hospitalized due to CHF by 23% [RR 0.77, (95% CI 0.68–0.87), P < 0.0001, I2 = 7%] and 
TM reduced this by 21% [RR 0.79, (95% CI 0.67–0.94), P = 0.008, I2 = 39%]. 
 
Addition of one STS study published as an abstract23 did not alter the result of the meta-analysis other than 
to reduce heterogeneity (I2 = 0%). Addition of two TM studies published as abstracts43,47 to the meta-
analysis marginally improved the effect [RR 0.76, (95% CI 0.64–0.89), P = 0.0006; I2 = 34%]. Excluding studies 
with a follow-up period of 6 months or less15,21,25,27–29,32 did not change the results of the meta-
analyses [STS: RR 0.76, (95% CI 0.65–0.89), P = 0.0005; I2 = 0%]. All TM studies reporting CHF-related 
hospitalizations had a follow-up period > 6 months. 
All-cause hospitalization 
Eleven studies of STS11,13,16,21,22,25,28–30,32,33 and eight studies of TM11,13,34,40–42,44,45 examined the effect of these 
interventions on the proportion of participants with at least one hospitalization for any cause (Figure 4). The 
effect of STS and TM on the risk of a hospitalization was similar [STS: RR 0.92, (95% CI 0.85–0.99), P = 0.02, I² 
= 24%; TM: RR 0.91, (95% CI 0.84–0.99), P = 0.02, I² = 78%]. 
 
 
No substantial change was observed in the results of the meta-analyses when studies published as abstracts 
were added23,43,47 [STS: RR 0.90 (95% 0.84–0.97), P = 0.003, I2 = 32%; TM: RR 0.94, (95% CI 0.87–1.01), P = 
0.09, I2 = 73%]. Excluding studies with a follow-up period of 6 months or less,21,25,28,29,32,41,44 did not 
substantially change the outcome [STS: RR 0.91, (95% CI 0.83–0.99), P = 0.03; I2 = 22%; TM: RR 0.87, (95% 
0.80–0.95), P = 0.002, I2 = 85%]. 
Length of stay 
Only one STS study32 reported a statistically significant reduction in the length of stay for patients in the 
intervention group compared with those receiving usual care. One study reported a substantial difference in 
the number of hospital days per patient.43 
Health-related quality of life 
Sixteen studies reported quality of life.14,15,17,19,22,27,29,30,33–35,37,39,41,44,45 These were either a direct comparison 
between the intervention and control groups at study conclusion, or between baseline and study conclusion 
within the study arm. A range of psychometric tools were used [Chronic Heart Failure Symptomatology 
Questionnaire; Minnesota Living with Heart Failure Questionnaire (MLWHFQ); Kansas City Cardiomyopathy 
Questionnaire (KCCM); Short-Form-12 Item; Short-Form-36 Item (SF-36); Health Distress Score]. 
Six studies of STS14,15,22,27,30,33 reported improvements in quality of life, with significant improvements in 
physical (P = 0.03)14 and overall measures (MLWHFQ and KCCM). Three TM studies,34,37,45,46 reported 
improvements in quality of life (MLWHFQ P = 0.001 and SF-36 mental (P = 0.001), and physical component 
scores (P = 0.003);37 MLWHFQ P = 0.025,46 and SF-36 P < 0.05;45 SF-36 health perception P = 0.04634). 
Cost 
Twelve studies (nine STS15,18,20,25,27–29,31–33 and three TM35,40,42) provided details on cost of the intervention or 
cost reductions associated with the intervention or cost effectiveness. The cost of the interventions varied 
according to the type of intervention, in particular the technologies used and the intensity at which it was 
delivered. Of the 11 studies which reported the effect of the intervention on the cost of care,18,20,25,27–
29,32,33,35,40,42 all but three,18,20,29,35 reported reductions in cost (either cost per admission or overall reduction 
in healthcare costs), with those reporting per cent reductions ranging between 14%25 and 86%.33 
Other outcomes 
Few studies reported adherence to the intervention (compliance). Among those that did,13,24,38,39,41,44 
adherence was measured at 65.8% for STS,24 and 75% to 98.5% for TM.13,38,39,41,44 The adaptation to the 
technology was high, with two studies, reporting that 96–97% of patients (often aged >70 years) were able 
to learn and use the STS or TM systems.12,24 Acceptance (satisfaction) of patients receiving healthcare via STS 
or TM was rated between 76%24 and 100%.12,24,35,42,45 Improvements in other outcomes from these trials 
included: New York Heart Association (NYHA) functional class that improved in three14,18,27 studies. Chronic 
heart failure knowledge and self-care improved in both studies reporting this outcome;17,35 6 min walk test 
improved in one study,27 of the two18 that reported this outcome; improvements in evidence-based 
pharmacotherapy were seen in six18,21,22,25,27,42 of the seven studies16 that reported this outcome and the only 
study to report brain natriuretic peptide, reported an improvement in this measure.37 
 
Discussion 
This systematic review and meta-analysis suggests that both TM and STS have a broad range of benefits for 
patients with heart failure: including a substantial reduction in all-cause mortality for TM, a substantial 
reduction in the risk of CHF hospitalization for both TM and STS and a modest reduction in the risk of all-
cause hospitalization. These interventions improved quality of life, reduced costs, and were acceptable to 
patients. Improvements in prescribing, patient knowledge and self-care, and functional class were observed. 
The precise mechanisms by which these interventions produce these effects are unclear but probably reflect 
a combination of improved implementation of and adherence to guideline therapies, early identification of 
complications or disease progression, and a positive impact on patient psychology.48 Patients in these trials 
reported a sense of reassurance and security, feeling that they have a lifeline to expert care.23,27 
 Two substantial studies49,50 have been reported since this review was completed and will be incorporated in 
the next revision which is currently underway. The Tele-HF study49 which included 1653 patients, was a study 
of a voice interactive system (STS) applied to patients recently discharged from hospital after an episode of 
worsening heart failure. Adherence with the system was very poor, suggesting that patients did not engage 
with the service, perhaps because of the nature of the technology. No benefits were observed on death or 
hospitalization. This is consistent with the results of our systematic review,7,51 at least with respect to 
mortality. The TIM-HF study,50,52,53 including 710 patients, was a TM study of patients with exceptionally 
well-managed chronic stable heart failure monitored by a remote expert group. Trends to fewer deaths and 
hospitalizations with TM were not significant; suggesting that home TM might not be an effective 
intervention in stable patients when other systems have ensured a high quality of care. However, TM might 
be a more efficient and less expensive option when the quality of care is not of a similar standard to that 
provided in TIM-HF. Also, it is unclear as to whether home TM is most successfully deployed as an adjunct to 
personalized care from a local specialist clinic or as a remote a regional or national service. 
We excluded from this analysis other methods of follow-up and management that have also been reported 
to improve outcomes, such as nurse-led or specialist heart failure clinic or home visits.2 
It is possible that intensified self-management and remote management are the key factors driving clinical 
benefit with these interventions. If so, the main issues revolve around an organization and cost 
effectiveness. The most expensive aspect of healthcare in high-income countries is staff to run services and 
deliver care. Delivering care by increasing direct one-to-one interactions is likely to be an expensive long-
term strategy. Development of TM systems that support the patient directly in making decisions about 
issues such as diuretic dose, diet, and life-style and when to seek professional advice have the potential to 
offer expert care to most patients with CHF. Implementation of TM will require a change in the approach of 
healthcare systems to the delivery of care with redeployment of existing staff rather than an expansion of 
the healthcare work force required by other strategies. Indeed, it is quite likely that TM has not worked 
optimally in clinical trials since the studies were generally done in parallel to rather than integrated with 
existing services. Restructuring healthcare around TM could be more effective and cost efficient. 
An additional and increasingly apparent dimension to TM is that it is a direct investment in the patient rather 
than in healthcare services. The patient is less likely to be a passive recipient of services from health 
professionals, and becomes more actively involved in their care. Patients provide information on symptoms 
and vital signs and receive feedback and education, which they can review at their leisure as often as they 
wish and together with their carers and family. More advanced systems will ensure that the patients know 
when and how medication should be adjusted and when they can do this themselves and when they need 
professional support. Because the patients know what care they should receive, health professionals may be 
more likely to deliver it or explain why the patients should deviate from the plan. Telemonitoring will create 
more expert patients. Undoubtedly, this will create headaches for health professionals, leading to resistance 
to change. The medical profession should offer the best service to patients even if this means moving out of 
their professional comfort zone. 
Compared with other recent systematic reviews of remote monitoring in CHF,54,55 our review7 is unique in 
using robust Cochrane methodology.8,9 We have synthesized and quantified the benefits of STS and TM, 
while limiting the influence of confounders such as home-visits by specialized healthcare staff or frequent 
visits to a specialized CHF clinic on the efficacy of these interventions in managing patients with CHF. 
Previous reviews on this topic have included a mixture of research methods (RCTs and cohort studies) and 
studies of both invasive and non-invasive remote monitoring, many of which have involved home visits.54,55 
These findings have important clinical implications. The findings of this review are highly relevant to the 
future planning and implementation of CHF disease-management globally. This analysis provides strong 
evidence that these technologies reduce mortality and hospitalizations as well as improving measures such 
as quality of life. There may be benefits of using these technologies to manage patients with CHF that relate 
to human or financial resources, but perhaps the biggest advantage can be gained from utilizing these 
technologies to reach patients with CHF who are without access to home or clinic-based CHF-management 
programmes.3,4 Such benefits may not be restricted to high-income countries. Indeed, China and India56 
both have programmes for delivering care remotely. 
The average age of patients in these included trials ranged from 45 to 78 years, with the majority of patients 
aged >68 years. It is clear that many older people are able to use and benefit from STS and TM. In fact TM 
devices are usually designed specifically with older people in mind. 
Our synthesis of the evidence of STS and TM is only as good as the included studies. We were limited by the 
format of published results, especially for those where we were unsuccessful in obtaining further study 
details. In addition, the heterogeneity is large for some of the meta-analyses of the primary outcomes. This 
heterogeneity is not only within methodology but also the types and intensity of applied technologies. 
There was evidence of publication bias. It is likely that many small studies are never published, either 
because the investigator does not offer their results for publication or because editors reject under-powered 
and negative studies. There is a dearth of evidence about how long patients should be supported by TM or 
STS. It is possible that the greatest benefit in terms of education and medication patterns is accrued within a 
few weeks and that long-term monitoring is redundant. However, the weight monitoring in heart failure trial 
showed that a 6-month TM intervention was associated with a reduction in mortality but that withdrawal 
led to rapid loss of this initial benefit, suggesting that long-term TM might be superior to short-term TM.57 
In conclusion, STS and TM improve outcomes for patients with CHF, although only TM appears to have a 
substantial impact on reducing mortality. This may reflect the impact of improved access to specialist care, 
which could be delivered by more conventional means but at additional cost. The effects appear substantial 
and might be an underestimate of the true impact when properly integrated into care pathways. Given the 
wealth of evidence and the impact on hospitalization that is likely to mitigate costs, all patients with CHF 
should have access to enhanced surveillance. 
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